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An exceptional year
As 2013 draws to a close, the world says goodbye to 
the man whose wisdom, forgiveness, and devotion to 
what was right gave rise to the South Africa we know 
today. The economic disparities between South Africa’s 
many ethnic groups may still peturb , but no one could 
watch a performance by Johannesburg’s Wits Choir 
and not give thanks to Nelson Mandela for nurturing 
a landscape in which these multitonal faces and voices 
could blend so naturally.
Mandela’s commitment to equality and against stigma 
also set South Africa on the path towards addressing 
what, after apartheid, became its next human rights 
catastrophe: HIV/AIDS. Following soaring increases in 
prevalence throughout the 1990s, the epidemic slowed 
into the 21st century and reached a peak around 2005—
the year in which Mandela announced publicly that his 
son had died of an HIV-related illness. South Africa now 
has the largest HIV treatment programme in the world, 
with an estimated 66% of eligible patients on treatment 
in 2011.
This ﬁ gure could change, however, as a result of 
new guidelines released by WHO earlier in 2013. The 
guidelines recommend that all adults with HIV be started 
on antiretroviral treatment when their CD4 cell count 
drops to 500 per μL—a substantially higher threshold 
than the previously recommended 350 cells per μL. How 
should a government such as South Africa’s respond? 
What is most cost-eﬀ ective and has the most health 
beneﬁ ts: to follow the guideline and increase the number 
of people on treatment as a result of the higher threshold; 
to continue to direct resources towards detection and 
follow-up of previously undiagnosed patients who may 
be more ill; or to expand some other programme?
Jeﬀ rey Eaton and colleagues’ Article in this month’s 
issue provides some answers. The paper, a project of the 
HIV Modelling Consortium, compares these scenarios 
in four diﬀ erent country settings using 12 existing 
mathematical models of the HIV epidemic. The results 
are reassuring with respect to the ambitiousness of the 
guideline and extremely useful for countries weighing 
up diﬀ erent strategies for advancing their HIV treatment 
programmes. To take South Africa as an example of 
a country with a generalised epidemic and moderate 
antiretroviral coverage, the combination of outputs 
from the models suggest that expansion of antiretroviral 
eligibility to 500 CD4 cells per μL would have a lower 
cost per disability-adjusted life-year (DALY) averted over 
20 years than would expansion of testing and linkage 
to care. In settings with lower baseline antiretroviral 
treatment coverage, the opposite is likely to be the case.
Once they start treatment, patients need to be 
monitored to check for non-adherence and treatment 
failure, and to prevent further transmission. Monitoring 
can be achieved clinically, immunologically (by 
measuring CD4 count), or virologically (by measuring 
viral load). The new WHO guidelines recommend 
that governments move away from immunological 
monitoring and towards viral load monitoring for 
people on antiretroviral therapy. Yet the latter is 
expensive and largely unavailable at the point of care. 
Is this recommendation likely to be cost-eﬀ ective and 
how should it be considered alongside the expanded 
eligibility guideline? In a further Article, again from the 
HIV Modelling Consortium, the answer is clear: viral load 
monitoring is the most eﬀ ective of the three monitoring 
strategies, but also the most costly; it should be rolled 
out only after countries have reached high antiretroviral 
coverage at the new threshold of 500 CD4 cells per μL.
Botswana is one country that has achieved high 
antiretroviral coverage at the previous criterion of 
350 CD4 cells per μL. An Article by Mansour Farahani and 
colleagues assesses the eﬀ ects on mortality of this ﬂ agship 
programme—the ﬁ rst national HIV/AIDS treatment 
programme in Africa. The programme enrolled 
140 patients in 2002, its ﬁ rst year, and by the end of 2012 
included more than 200 000. That deaths in patients 
on the programme decrease from 12·8 per 100 person-
years within the ﬁ rst 3 months to 1·16 per 100 person-
years after 1 year is testament to the eﬀ ectiveness of the 
programme. Nevertheless, more than 15 000 patients 
were lost to follow-up over the 9-year period studied, 
indicating a need to address the reasons why people leave 
this free-of-charge programme.
François Dabis states in a Comment, “2013 will 
be remembered as an exceptional year in shaping 
our strategy to control HIV/AIDS”. It will be, and 
Nelson Mandela’s legacy will be no small part of that.
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